Clinical management of tuberculosis and HIV-1 co-infection

European Respiratory Journal

Volumn 36, Issue 6, 2010, Pages 1460-1481

  Schutz, C ^a,b   Meintjes, G ^a,b,c   Almajid, F ^d   Wilkinson, R J ^a,b,c,e   Pozniak, A ^d  

^a GF Jooste Hospital   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Complications; Diagnosis; HIV 1; Management; Mycobacterium tuberculosis

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DEXAMETHASONE; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; ETHAMBUTOL; ETRAVIRINE; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PREDNISOLONE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RILPIVIRINE; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTHRALGIA; BONE MARROW SUPPRESSION; CHEMOPROPHYLAXIS; DIRECTLY OBSERVED THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER TOXICITY; LOW DRUG DOSE; LUNG TUBERCULOSIS; MIXED INFECTION; MONOTHERAPY; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RETROBULBAR OPTIC NEUROPATHY; REVIEW; SERODIAGNOSIS; SHORT COURSE THERAPY; SIDE EFFECT; SPUTUM ANALYSIS; SYMPTOM; TUBERCULOUS MENINGITIS; TUBERCULOUS PERICARDITIS; UVEITIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; EXANTHEMA; FEMALE; HEPATITIS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL NERVOUS SYSTEM DISEASES; TUBERCULOSIS; VIRAL LOAD;

EID: 78649754323     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00110210     Document Type: Review

References (262)

1. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23: 75-80. (Pubitemid 30123268)
2. Burman WJ, Jones BE. Clinical and radiographic features of HIV-related tuberculosis. Semin Respir Infect 2003; 18: 263-271. (Pubitemid 38018770)
3. Mukadi Y, Perriens JH, St Louis ME, et al. Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet 1993; 342: 143-146.
4. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African Gold Miners. J Infect Dis 2005; 191: 150-158. (Pubitemid 40096371)
5. Hopewell PC. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis. Clin Infect Dis 1992; 15: 540-547.
6. Wallis RS, Johnson JL. Adult tuberculosis in the 21st century: pathogenesis, clinical features, and management. Curr Opin Pulm Med 2001; 7: 124-132. (Pubitemid 32466278)
7. Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148: 1292-1297. (Pubitemid 2004673)
8. Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment. Bull World Health Organ 1992; 70: 515-526.
9. Harries AD, Maher D, Nunn P. An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa. Bull World Health Organ 1998; 76: 651-662. (Pubitemid 29143879)
10. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181: 80-86.
11. Brust JC, Gandhi NR, Carrara H, et al. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis 2010; 14: 413-419.
12. Bruchfeld J, Aderaye G, Palme IB, et al. Evaluation of outpatients with suspected pulmonary tuberculosis in a high HIV prevalence setting in Ethiopia: clinical, diagnostic and epidemiological characteristics. Scand J Infect Dis 2002; 34: 331-337. (Pubitemid 34746250)
13. Batungwanayo J, Taelman H, Dhote R, et al. Pulmonary tuberculosis in Kigali, Rwanda. Impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am Rev Respir Dis 1992; 146: 53-56.
14. Selwyn PA, Pumerantz AS, Durante A, et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. AIDS 1998; 12: 885-893. (Pubitemid 28241402)
15. Kassu A, Mengistu G, Ayele B, et al. Coinfection and clinical manifestations of tuberculosis in human immunodeficiency virus-infected and -uninfected adults at a teaching hospital, northwest Ethiopia. J Microbiol Immunol Infect 2007; 40: 116-122.
16. Garcia GF, Moura AS, Ferreira CS, et al. Clinical and radiographic features of HIV-related pulmonary tuberculosis according to the level of immunosuppression. Rev Soc Bras Med Trop 2007; 40: 622-626.
17. Banda HT, Harries AD, Welby S, et al. Prevalence of tuberculosis in TB suspects with short duration of cough. Trans R Soc Trop Med Hyg 1998; 92: 161-163. (Pubitemid 28200790)
18. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010; 362: 707-716.
19. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40: 1500-1507.
20. Swaminathan S, Paramasivan CN, Kumar SR, et al. Unrecognised tuberculosis in HIV-infected patients: sputum culture is a useful tool. Int J Tuberc Lung Dis 2004; 8: 896-898. (Pubitemid 38937608)
21. Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175: 87-93. (Pubitemid 46105314)
22. Lawn SD, Edwards DJ, Kranzer K, et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23: 1875-1880.
23. Bassett Ingrid V, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51: 823-829.
24. Friedland G, Harries A, Coetzee D. Implementation issues in tuberculosis/HIV program collaboration and integration: 3 case studies. J Infect Dis 2007; 196: S114-S123. (Pubitemid 47206090)
25. Kumar P, Sharma N, Sharma NC, et al. Clinical profile of tuberculosis in patients with HIV Infection/AIDS. Indian J Chest Dis Allied Sci 2002; 44: 159-163.
26. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9: 173-184.
27. Chaisson RE, Schecter GF, Theuer CP, et al. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis 1987; 136: 570-574.
28. Alpert PL, Munsiff SS, Gourevitch MN, et al. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Clin Infect Dis 1997; 24: 661-668.
29. Lucas SB, De Cock KM, Hounnou A, et al. Contribution of tuberculosis to slim disease in Africa. BMJ 1994; 308: 1531-1533. (Pubitemid 24178450)
30. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg 1993; 96: 1-11.
31. Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res 2004; 120: 316-353.
32. Pallangyo KJ. Clinical features of tuberculosis among adults in sub-Saharan Africa in the 21st century. Scand J Infect Dis 2001; 33: 488-493.
33. Sinkala E, Gray S, Zulu I, et al. Clinical and ultrasonographic features of abdominal tuberculosis in HIV positive adults in Zambia. BMC Infect Dis 2009; 9: 44.
34. McDonald LC, Archibald LK, Rheanpumikankit S, et al. Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries. Lancet 1999; 354: 1159-1163.
35. Wilson D, Nachega JB, Chaisson RE, et al. Diagnostic yield of peripheral lymph node needle-core biopsies in HIV-infected adults with suspected smear-negative tuberculosis. Int J Tuberc Lung Dis 2005; 9: 220-222.
36. Hill AR, Premkumar S, Brustein S, et al. Disseminated tuberculosis in the acquired immunodeficiency syndrome era. Am Rev Respir Dis 1991; 144: 1164-1170.
37. Vadillo M, Corbella X, Carratala J. AIDS presenting as septic shock caused by Mycobacterium tuberculosis. Scand J Infect Dis 1994; 26: 105-106.
38. Wilson D, Nachega J, Morroni C, et al. Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults. Int J Tuberc Lung Dis 2006; 10: 31-38.
39. Croda MG, Vidal JE, Hernandez AV, et al. Tuberculous meningitis in HIV-infected patients in Brazil: clinical and laboratory characteristics and factors associated with mortality. Int J Infect Dis 2010; 14: e586-e591.
40. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med 1992; 326: 668-672.
41. Azuaje C, Fernandez Hidalgo N, Almirante B, et al. Tuberculous meningitis: a comparative study in relation to concurrent human immunodeficiency virus infection. Enferm Infecc Microbiol Clin 2006; 24: 245-250.
42. Thwaites GE, Duc Bang N, Huy Dung N, et al. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J Infect Dis 2005; 192: 2134-2141.
43. Karstaedt AS, Valtchanova S, Barriere R, et al. Tuberculous meningitis in South African urban adults. QJM 1998; 91: 743-747.
44. Yechoor VK, Shandera WX, Rodriguez P, et al. Tuberculous meningitis among adults with and without HIV infection. Experience in an urban public hospital. Arch Intern Med 1996; 156: 1710-1716.
45. Lertsrisatit P, Nantiruj K, Totemchokchyakarn K, et al. Extraspinal tuberculous arthritis in HIV era. Clin Rheumatol 2007; 26: 319-321.
46. Canueto-Quintero J, Caballero-Granado FJ, Herrero-Romero M, et al. Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study. Clin Infect Dis 2003; 37: 584-590.
47. Ntsekhe M, Wiysonge CS, Gumedze F, et al. HIV infection is associated with a lower incidence of constriction in presumed tuberculous pericarditis: a prospective observational study. PLoS One 2008; 3: e2253.
48. Corbett EL, Charalambous S, Moloi VM, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004; 170: 673-679.
49. Corbett EL, Bandason T, Cheung YB, et al. Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and implications for control. Int J Tuberc Lung Dis 2009; 13: 1231-1237.
50. Nyamande K, Lalloo UG, John M. TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence. Int J Tuberc Lung Dis 2007; 11: 1308-1313.
51. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 2010; 5: 18-26.
52. Rana FS, Hawken MP, Mwachari C, et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr 2000; 24: 23-29.
53. Murray J, Sonnenberg P, Shearer S, et al. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159: 733-740.
54. Schmaltz CA, Sant'Anna FM, Neves SC, et al. Influence of HIV infection on mortality in a cohort of patients treated for tuberculosis in the context of wide access to HAART, in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2009; 52: 623-628.
55. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg 1995; 89: 78-82.
56. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009; 17: 183-188.
57. Barry 3rd CE, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7: 845-855.
58. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973.
59. Corbett EL, Bandason T, Cheung YB, et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 2007; 4: e22.
60. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993; 342: 332-337. (Pubitemid 23227562)
61. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
62. Glynn JR, Crampin AC, Ngwira BM, et al. Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988- 2001. AIDS 2004; 18: 1459-1463.
63. Alland D, Kalkut GE, Moss AP, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1710-1716.
64. Maartens G, Wilkinson RJ. Tuberculosis. Lancet 2007; 370: 2030-2043.
65. Graham NM, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and - seronegative intravenous drug users. JAMA 1992; 267: 369-373.
66. Selwyn PA, Sckell BM, Alcabes P, et al. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992; 268: 504-509.
67. Markowitz N, Hansen NI, Wilcosky TC, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary complications of HIV Infection Study Group. Ann Intern Med 1993; 119: 185-193.
68. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175: 514-520.
69. Sorensen AL, Nagai S, Houen G, et al. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 1995; 63: 1710-1717.
70. Berthet FX, Rasmussen PB, Rosenkrands I, et al. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998; 144: 3195-3203.
71. Aagaard C, Brock I, Olsen A, et al. Mapping immune reactivity toward Rv2653 and Rv2654: two novel low-molecular-mass antigens found specifically in the Mycobacterium tuberculosis complex. J Infect Dis 2004; 189: 812-819.
72. Van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009; 180: 49-58.
73. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
74. Oni T, Patel J, Gideon HP, et al. Enhanced diagnosis of HIV-1 associated tuberculosis by relating T-SPOT.TB and CD4 counts. Eur Respir J 2010; 36: 594-600.
75. Millington KA, Innes JA, Hackforth S, et al. Dynamic relationship between IFN-c and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol 2007; 178: 5217-5226.
76. Dietrich J, Andersen C, Rappuoli R, et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 2006; 177: 6353-6360.
77. Vordermeier HM, Chambers MA, Cockle PJ, et al. Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect Immun 2002; 70: 3026-3032.
78. Ribeiro S, Dooley K, Hackman J, et al. T-SPOT.TB responses during treatment of pulmonary tuberculosis. BMC Infect Dis 2009; 9: 23.
79. Leidl L, Mayanja-Kizza H, Sotgiu G, et al. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+T-cells in HIV infection. Eur Respir J 2010; 35: 619-626.
80. Sester M, Giehl C, Sester U, et al. Management of tuberculosis in HIV infection: where T-cells matter. Eur Respir J 2010; 35: 475-476.
81. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48: 954-962.
82. Brock I, Ruhwald M, Lundgren B, et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006; 7: 56.
83. Jones S, de Gijsel D, Wallach FR, et al. Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. Int J Tuberc Lung Dis 2007; 11: 1190-1195.
84. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175: 737-742.
85. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009; 136: 198-204.
86. Talati NJ, Seybold U, Humphrey B, et al. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009; 9: 15.
87. Stephan C, Wolf T, Goetsch U, et al. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS 2008; 22: 2471-2479.
88. Perkins MD. New diagnostic tools for tuberculosis. Int J Tuberc Lung Dis 2000; 4: Suppl. 2, S182-S188.
89. Yu JK, Bong CN, Chen SC, et al. Outcomes in HIV-infected patients who develop tuberculosis after starting antiretroviral treatment in Malawi. Int J Tuberc Lung Dis 2008; 12: 692-694.
90. Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1997; 25: 242-246.
91. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353: 444-449.
92. Small PM, Schecter GF, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324: 289-294.
93. Fournier AM, Dickinson GM, Erdfrocht IR, et al. Tuberculosis and nontuberculous mycobacteriosis in patients with AIDS. Chest 1988; 93: 772-775.
94. Churchyard GJ, Kleinschmidt I, Corbett EL, et al. Mycobacterial disease in South African gold miners in the era of HIV infection. Int J Tuberc Lung Dis 1999; 3: 791-798.
95. Nunn P, Mungai M, Nyamwaya J, et al. The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. Tuber Lung Dis 1994; 75: 25-32. (Pubitemid 24128756)
96. Smith RL, Yew K, Berkowitz KA, et al. Factors affecting the yield of acid-fast sputum smears in patients with HIV and tuberculosis. Chest 1994; 106: 684-686.
97. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis 1992; 146: 849-854.
98. Long R, Maycher B, Scalcini M, et al. The chest roentgenogram in pulmonary tuberculosis patients seropositive for human immunodeficiency virus type 1. Chest 1991; 99: 123-127.
99. Long R, Scalcini M, Manfreda J, et al. Impact of human immunodeficiency virus type 1 on tuberculosis in rural Haiti. Am Rev Respir Dis 1991; 143: 69-73.
100. Long R, Scalcini M, Manfreda J, et al. The impact of HIV on the usefulness of sputum smears for the diagnosis of tuberculosis. Am J Public Health 1991; 81: 1326-1328.
101. Elliott AM, Luo N, Tembo G, et al. Impact of HIV on tuberculosis In Zambia: a cross sectional study. BMJ 1990; 301: 412-415.
102. Klein NC, Duncanson FP, Lenox TH 3rd, et al. Use of mycobacterial smears in the diagnosis of pulmonary tuberculosis in AIDS/ARC patients. Chest 1989; 95: 1190-1192.
103. Furin JJ, Johnson JL. Recent advances in the diagnosis and management of tuberculosis. Curr Opin Pulm Med 2005; 11: 189-194.
104. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6: 570-581. (Pubitemid 44262344)
105. Marais BJ, Brittle W, Painczyk K, et al. Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clin Infect Dis 2008; 47: 203-207.
106. Lillehei JP. Sputum induction with heated aerosol inhalations for the diagnosis of tuberculosis. Am Rev Respir Dis 1961; 84: 276-278.
107. Hartung TK, Maulu A, Nash J, et al. Suspected pulmonary tuberculosis in rural South Africa: sputum induction as a simple diagnostic tool? S Afr Med J 2002; 92: 455-458.
108. Parry CM, Kamoto O, Harries AD, et al. The use of sputum induction for establishing a diagnosis in patients with suspected pulmonary tuberculosis in Malawi. Tuber Lung Dis 1995; 76: 72-76.
109. Post FA, Wood R, Pillay GP. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+T-lymphocyte count. Tuber Lung Dis 1995; 76: 518-521.
110. World Health Organization. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource constrained settings. Geneva, World Health Organization, 2006. www.who.int/tb/publications/ 2006/tbhiv-recommendations.pdf
111. Colebunders R, Bastian I. A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 97-107.
112. Siddiqi K, Lambert ML, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis 2003; 3: 288-296.
113. Saltini C. Chemotherapy and diagnosis of tuberculosis. Respir Med 2006; 100: 2085-2097.
114. Williams-Bouyer N, Yorke R, Lee HI, et al. Comparison of the BACTEC MGIT 960 and ESP culture system II for growth and detection of mycobacteria. J Clin Microbiol 2000; 38: 4167-4170.
115. Caviedes L, Lee TS, Gilman RH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. J Clin Microbiol 2000; 38: 1203-1208.
116. Caws M, Dang TM, Torok E, et al. Evaluation of the MODS culture technique for the diagnosis of tuberculous meningitis. PLoS One 2007; 2: e1173.
117. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355: 1539-1550.
118. Flores LL, Pai M, Colford JM Jr, et al. In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression. BMC Microbiol 2005; 5: 55.
119. Ling DI, Flores LL, Riley LW, et al. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One 2008; 3: e1536.
120. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48: 229-237.
121. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32: 1165-1174.
122. Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16: 2285-2293.
123. Baba K, Sornes S, Hoosen AA, et al. Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON TB-Gold interferon-gamma assay. BMC Infect Dis 2008; 8: 35.
124. Cattamanchi A, Ssewenyana I, Davis JL, et al. Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. BMC Infect Dis 2010; 10: 75.
125. Raby E, Moyo M, Devendra A, et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One 2008; 3: e2489.
126. Seshadri C, Uiso LO, Ostermann J, et al. Low sensitivity of T-cell based detection of tuberculosis among HIV co-infected Tanzanian in-patients. East Afr Med J 2008; 85: 442-449.
127. Syed Ahamed Kabeer B, Sikhamani R, Swaminathan S, et al. Role of interferon gamma release assay in active TB diagnosis among HIV infected individuals. PLoS One 2009; 4: e5718.
128. Tsiouris SJ, Coetzee D, Toro PL, et al. Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis. J Clin Microbiol 2006; 44: 2844-2850.
129. Clark SA, Martin SL, Pozniak A, et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007; 150: 238-244.
130. Rangaka MX, Diwakar L, Seldon R, et al. Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin Infect Dis 2007; 44: 1639-1646.
131. Steingart KR, Dendukuri N, Henry M, et al. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol 2009; 16: 260-276.
132. Steingart KR, Henry M, Laal S, et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 2007; 4: e202.
133. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154: 1034-1038.
134. Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13: 1899-1904.
135. Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9: 1185-1191.
136. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175: 1199-1206.
137. El-Sadr WM, Perlman DC, Denning E, et al. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001; 32: 623-632.
138. Golub JE, Durovni B, King BS, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008; 22: 2527-2533.
139. El-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of shortcourse treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998; 26: 1148-1158.
140. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1998; 53: 536-548.
141. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and metaanalysis. Clin Infect Dis 2010; 50: 1288-1299.
142. Sotgiu G, Centis R, D'Ambrosio L, et al. Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. Eur Respir J 2010; 36: 208-211.
143. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
144. Farmer P, Leandre F, Mukherjee J, et al. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ 2001; 79: 1145-1151.
145. Alwood K, Keruly J, Moore-Rice K, et al. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994; 8: 1103-1108.
146. Swaminathan S, Narendran G, Venkatesan P, et al. Acquired rifampicin resistance in HIV-infected and -uninfected patients with TB treated with a thrice-weekly short-course regimen. Abstract 783. 16th Conference on Retrovirusses and Opportunistic Infections, Montreal, Canada, 2009.
147. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51: 214-215.
148. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353: 1843-1847.
149. Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38: 731-736.
150. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350-356.
151. Mayanja-Kizza H, Jones-Lopez E, Okwera A, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005; 191: 856-865.
152. Elliott AM, Luzze H, Quigley MA, et al. A randomized, doubleblind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 2004; 190: 869-878.
153. Hakim JG, Ternouth I, Mushangi E, et al. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 2000; 84: 183-188.
154. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-1751.
155. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008; 1: CD002244.
156. Li AP, Reith MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 1997; 107: 17-30.
157. Rae JM, Johnson MD, Lippman ME, et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299: 849-857.
158. Perucca E, Grimaldi R, Frigo GM, et al. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988; 34: 595-599.
159. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14: 1039-1043.
160. Schuetz EG, Schinkel AH, Relling MV, et al. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 1996; 93: 4001-4005.
161. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007; 4: CD005159.
162. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, et al. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. Tuber Lung Dis 1994; 75: 341-347.
163. McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154: 1462-1467.
164. Schwander S, Rusch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis 1995; 76: 210-218.
165. Narita M, Stambaugh JJ, Hollender ES, et al. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis 2000; 30: 779-783.
166. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41: 681-690.
167. Soy D, Lopez E, Sarasa M, et al. Population pharmacokinetic modeling in HIV patients with tuberculosis treated with efavirenz and rifampicin. Abstract 15. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec City, Canada, 2005.
168. Matteelli A, Regazzi M, Villani P, et al. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 2007; 5: 349-353.
169. -1 in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20: 131-132.
170. Pedral-Sampaio DB, Alves CR, Netto EM, et al. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infect Dis 2004; 8: 211-216.
171. Orrell C, Cohen K, Ive P, et al. O124 efavirenz and rifampicin in the South African context: is there a need to dose increase efavirenz with concurrent rifampicin therapy? J Int AIDS Soc 2008; 11: Suppl. 1, O9.
172. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530-539.
173. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob Agents Chemother 2009; 53: 4545-4548.
174. -1) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58: 1299-1302.
175. Schouten JT, Krambrink A, Ribaudo HJ, et al. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis 2010; 50: 787-791.
176. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42: 401-407.
177. Brennan-Benson P, Lyus R, Harrison T, et al. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 2005; 19: 1541-1543.
178. Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS 2010; 5: 61-69.
179. Oliva J, Moreno S, Sanz J, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS 2003; 17: 637-638.
180. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001; 28: 450-453.
181. Robinson P, Lamson M, Gigliotti M, et al. Pharmacokinetic interaction between nevirapine and rifampicin. Abstract 60623. 12th World AIDS conference, Geneva, Switzerland, 1998.
182. Autar RS, Wit FW, Sankote J, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005; 10: 937-943.
183. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008; 61: 389-393.
184. Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther 2008; 13: 529-536.
185. Van Cutsem G, Cohen K, Bedelu M. TB/HIV co-infected patients on rifampicin containing treatment have equivalent ART treatment outcomes, and concurrent use of nevirapine is not associated with increase in hepatotoxicity. Abstract WePp0303. 3rd Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 2005.
186. Van Heeswijk R, Hoetelmans R, Kestens D, et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). Abstract 74. 7th International Workshop on Clinical Pharmacology of HIV Therapy Lisbon, Portugal, 2006.
187. La Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 1553-1560.
188. Nijland HM, L'Homme RF, Rongen GA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008; 22: 931-935.
189. Veldkamp AI, Hoetelmans RM, Beijnen JH, et al. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999; 29: 1586.
190. Ribera E, Azuaje C, Lopez RM, et al. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). J Acquir Immune Defic Syndr 2005; 40: 317-323.
191. Ribera E, Azuaje C, Lopez RM, et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother 2007; 59: 690-697.
192. Schmitt C, Riek M, Winters K, et al. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf 2009; 2: 8-16.
193. Acosta EP, Kendall MA, Gerber JG, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007; 51: 3104-3110.
194. Burger DM, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3336-3342.
195. Mallolas J, Sarasa M, Nomdedeu M, et al. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007; 8: 131-134.
196. Boehringer Ingelheim Pharmaceuticals Inc. AptivusR package insert. 2005.
197. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49: 1305-1311.
198. L'Homme R F, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009; 23: 863-865.
199. DART Virology Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20: 1391-1399.
200. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20: 1391-1399.
201. Srikantiah P, Walusimbi MN, Kayanja HK, et al. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS 2007; 21: 1972-1974.
202. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850-1861.
203. Armstrong-James D, Menon-Johansson A, Pozniak A. The utility of nucleos(t)ide-only regimens in the treatment of Mycobacterium tuberculosis-HIV-1 coinfection. AIDS 2009; 23: 865-867.
204. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53: 2852-2856.
205. Abel S, Jenkins TM, Whitlock LA, et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008; 65: Suppl. 1, 38-46. (Pubitemid 351366537)
206. Patel IH, Zhang X, Nieforth K, et al. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005; 44: 175-186.
207. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251.
208. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration. Lancet 1994; 344: 1323-1328.
209. Coyne KM, Pozniak AL, Lamorde M, et al. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009; 23: 437-446.
210. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477.
211. Devoto FM, Gonzalez C, Iannantuono R, et al. Risk factors for hepatotoxicity induced by antituberculosis drugs. Acta Physiol Pharmacol Ther Latinoam 1997; 47: 197-202.
212. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16: 75-83.
213. Breen RA, Miller RF, Gorsuch T, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006; 61: 791-794.
214. Breen RA, Lipman MC, Johnson MA. Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals. AIDS 2000; 14: 615.
215. Westreich DJ, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009; 48: 1617-1623.
216. Kura MM, Hira SK. Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitization. Int J Dermatol 2001; 40: 481-484.
217. Galloe AM, Graudal N, Christensen HR, et al. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48: 39-43.
218. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23: 689-696.
219. Blanc FX, Havlir DV, Onyebujoh PC, et al. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007; 196: Suppl. 1, S46-S51.
220. Churchyard GJ, Kleinschmidt I, Corbett EL, et al. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 705-712.
221. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
222. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-341.
223. Blanc FX, Sok T, Laureillard D, et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. Abstract THLBB106. 18th International AIDS Conference, Vienna, Austria, 2010.
224. Torok M, Yen N, Chau T, et al. Randomised controlled trial of immediated versus deferred antiretroviral therapy in HIV-associated tuberculosis meningitis. Abstract H-1224. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, United States of America, 2009.
225. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001; 164: 7-12.
226. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
227. Moreno S. Antiviral therapy and tuberculosis, Abstract TuOr171. 14th World AIDS Conference, Barcelona, Spain, 2002.
228. Navas E, Oliva J, Miralles P. Antiretroviral therapy in AIDS patient. Abstract ThPeB7271. 14th World AIDS Conference, Barcelona, Spain, 2002.
229. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-1627.
230. Marais S, Wilkinson RJ, Pepper DJ, et al. Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep 2009; 6: 162-171.
231. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-523.
232. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-161.
233. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59: 704-707.
234. Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39: 1709-1712.
235. Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53: 357-363.
236. Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009; 48: 667-676.
237. Manosuthi W, Van Tieu H, Mankatitham W, et al. Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2009; 23: 2467-2471.
238. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009; 48: e96-e107.
239. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19: 399-406.
240. Michailidis C, Pozniak AL, Mandalia S, et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005; 10: 417-422.
241. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007; 11: 1282-1289.
242. Haddow LJ, Moosa MY, Easterbrook PJ. Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS, 24: 103-108.
243. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstruction inflammatory syndrome. AIDS 2010; 24: 2381-2390.
244. Elliott AM, Halwiindi B, Bagshawe A, et al. Use of prednisolone in the treatment of HIV-positive tuberculosis patients. Q J Med 1992; 85: 855-860.
245. Volkow PF, Cornejo P, Zinser JW, et al. Life-threatening exacerbation of Kaposi's sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. AIDS 2008; 22: 663-665.
246. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21: 2483-2491.
247. Brinkhof MW, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45: 1518-1521.
248. Lawn SD, Wilkinson RJ, Lipman MC, et al. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177: 680-685.
249. Lawn SD, Wainwright H, Orrell C. Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS 2009; 23: 143-145.
250. Goldsack NR, Allen S, Lipman MC. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect 2003; 79: 337-338.
251. Crump JA, Tyrer MJ, Lloyd-Owen SJ, et al. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis 1998; 26: 1008-1009.
252. Tahir M, Sinha S, Sharma SK, et al. Immune reconstitution inflammatory syndrome manifesting as disseminated tuberculosis, deep venous thrombosis, encephalopathy and myelopathy. Indian J Chest Dis Allied Sci 2008; 50: 363-364.
253. Chen WL, Lin YF, Tsai WC, et al. Unveiling tuberculous pyomyositis: an emerging role of immune reconstitution inflammatory syndrome. Am J Emerg Med 2009; 27: e251-e252.
254. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009; 48: 829-831.
255. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; 1: CD000171.
256. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102.
257. Kranzer K, Houben RM, Glynn JR, et al. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 93-102.
258. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979; 119: 827-830.
259. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15: 2137-2147.
260. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15: 215-222.
261. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-2457.
262. Samandari T. Randomized, placebo controlled trial of 6 vs 34 months of isoniazid TB preventative therapy for HIV-infected adults in Botswana. Paper #104LB. 17th Conference on Retrovirusses and Opportunistic Infections. San Francisco, USA, 2009.